



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

July 20, 2023

Nassim Usman, Ph.D.  
President and Chief Executive Officer  
Catalyst Biosciences, Inc.  
611 Gateway Blvd  
Suite 120  
South San Francisco, CA 94080

**Re: Catalyst Biosciences, Inc.**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed March 30, 2023**  
**File No. 000-51173**

Dear Nassim Usman:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Stephen B. Thau, Esq.